Form 4: Immix Biopharma Director Magda Marquet Reports Stock Option Grant and Beneficial Ownership Changes

Director Magda Marquet reports acquisition of stock options and changes in beneficial ownership of Immix Biopharma, Inc. shares.

Summary

• Magda Marquet, a director of Immix Biopharma, Inc. [IMMX], filed a Form 4 on June 21, 2024, reporting changes in beneficial ownership.
• The report details the acquisition of 33,000 stock options with an exercise price of $2.04, vesting in equal monthly installments over twelve months, and expiring on June 11, 2034.
• Marquet directly owns 46,092 shares of common stock.
• She also indirectly owns 20,000 shares of common stock via ALMA Life Sciences, LLC.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants and ownership changes. The acquisition of options could be seen as a slightly positive sign, but it's not a major event.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, aligning the director's interests with those of the shareholders.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. Investors monitor these filings for insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• Shareholders may view the stock option grant as aligning the director's interests with the company's performance.

Key Dates